Moore Capital Management LP Has $21.02 Million Holdings in argenex SE $ARGX

Moore Capital Management LP grew its position in argenex SE (NASDAQ:ARGX) by 66.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,000 shares of the company’s stock after purchasing an additional 10,000 shares during the period. Moore Capital Management LP’s holdings in argenex were worth $21,024,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Oppenheimer & Co. Inc. increased its position in argenex by 2.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after purchasing an additional 12 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after acquiring an additional 12 shares in the last quarter. CI Investments Inc. boosted its stake in shares of argenex by 2.6% during the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after acquiring an additional 12 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in shares of argenex by 3.4% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock worth $292,000 after acquiring an additional 13 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in shares of argenex by 12.7% during the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after acquiring an additional 13 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Trading Up 1.6%

Shares of ARGX stock opened at $892.26 on Thursday. The stock has a 50 day moving average of $820.36 and a two-hundred day moving average of $810.81. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The company has a market capitalization of $55.49 billion, a P/E ratio of 39.73, a P/E/G ratio of 1.34 and a beta of 0.47.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion during the quarter. Sell-side analysts predict that argenex SE will post 26.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Guggenheim upped their price target on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Oppenheimer decreased their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research note on Thursday, April 2nd. Robert W. Baird increased their target price on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Wedbush restated an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research note on Thursday, June 11th. Finally, Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.